LICENSING AGREEMENTS (Details Narrative) (USD $)	12 Months Ended	0 Months Ended			9 Months Ended	0 Months Ended
	Mar. 31, 2014	Dec. 27, 2013	Jul. 28, 2006	Feb. 24, 2010	Dec. 31, 2014	Aug. 01, 2013	Sep. 22, 2006	Apr. 18, 2011
Acquired Finite Lived Intangible Assets [Line Items]
Licensing agreement acquired	$ 9,902,900
3M Acquisition [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Payment for business acquisition		7,000,000
Discount rate		26.50%
WACC Premium		5.00%
Viral Therapies Licensing Agreements [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Maximum licensing payments			10,000,000
Viral Therapies Licensing Agreements [Member] | Maximum [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Milestone payment					900,000
Viral Therapies Licensing Agreements [Member] | Officer [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Rights to purchase shares of common stock			1,000,000
Exercise price of share purchase rights			$ 0.001
Influenza Vaccine Licensing Agreements [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Payment to be made upon commencement							70,000
Total licensing payments to be made							283,420
Colby Pharmaceuticals Licensing Agreements [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Shares issued for licensing agreements				294,118
Percentage to be paid from amount received under each agreement entered into before IND application is filed with the FDA					40.00%
Percentage to be paid from amount received under each agreement entered into after IND application until completion of a Phase I clinical trial					30.00%
Percentage to be paid from amount received under each agreement entered into from completion of a Phase I clinical trial through completion of a Phase II clinical trial					25.00%
Percentage to be paid from amount received under each agreement entered into from completion of a Phase II clinical trial until a NDA is approved by the FDA					20.00%
Percentage to be paid from amount received under each agreement entered into after the NDA has been approved by the FDA					10.00%
Colby Pharmaceuticals Licensing Agreements [Member] | Upon filing of the first IND or comparable regulatory filing for a human therapeutic product [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Milestone payment					25,000
Colby Pharmaceuticals Licensing Agreements [Member] | Upon enrollment of first patient under a Phase II clinical trial for the first human therapeutic product [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Milestone payment					150,000
Colby Pharmaceuticals Licensing Agreements [Member] | Upon enrollment of first patient under a Phase III clinical trial for the first human therapeutic product [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Milestone payment					200,000
Colby Pharmaceuticals Licensing Agreements [Member] | Upon the first NDA or comparable regulatory approval for a human therapeutic product [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Milestone payment					250,000
Colby Pharmaceuticals Licensing Agreements [Member] | Colby Pharmaceuticals [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Shares acquired for licensing agreements				47,059
Colby Pharmaceuticals Licensing Agreements [Member] | Related Party 1 [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Shares issued for licensing agreements				73,529
Colby Pharmaceuticals Licensing Agreements [Member] | Related Party 2 [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Shares issued for licensing agreements				73,529
Regents of the University of California and Dana-Farber Cancer Institute Licensing Agreements [Member]
Acquired Finite Lived Intangible Assets [Line Items]
License issue fee payable								10,000
License maintenance fees payable on the first through third anniversary					10,000
License maintenance fees payable after the third anniversary through commercial sale of a product					20,000
Earned royalty to be paid on net sales of licensed products					2.00%
License fees and reimbursed patent costs paid	100,000				10,000
Regents of the University of California and Dana-Farber Cancer Institute Licensing Agreements [Member] | Upon dosing of 50% of the patients expected to be enrolled for a Phase I clinical trial for the first indication of a licensed product [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Milestone payment					25,000
Regents of the University of California and Dana-Farber Cancer Institute Licensing Agreements [Member] | Upon filing of an IND for the second indication of a licensed product [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Milestone payment					25,000
Regents of the University of California and Dana-Farber Cancer Institute Licensing Agreements [Member] | Upon dosing of the first patient in a Phase II clinical trial for the first indication of a licensed product [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Milestone payment					100,000
Regents of the University of California and Dana-Farber Cancer Institute Licensing Agreements [Member] | Upon dosing of the 40th patient in a Phase II clinical trial for the first indication of a licensed product [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Milestone payment					150,000
Regents of the University of California and Dana-Farber Cancer Institute Licensing Agreements [Member] | Upon dosing of the first patient in a Phase II clinical trial for the second indication of a licensed product [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Milestone payment					250,000
Regents of the University of California and Dana-Farber Cancer Institute Licensing Agreements [Member] | Upon dosing of the first patient in a Phase III clinical trial for the first indication of a licensed product [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Milestone payment					600,000
Regents of the University of California and Dana-Farber Cancer Institute Licensing Agreements [Member] | Upon dosing of the first patient in a Phase III clinical trial for the second indication of a licensed product [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Milestone payment					600,000
Regents of the University of California and Dana-Farber Cancer Institute Licensing Agreements [Member] | Upon receipt of US Regulatory approval for each indication of a licensed product [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Milestone payment					1,000,000
3M Licensing Agreements [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Licensing agreement acquired						$ 3,000,000